Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.
Villanueva, Jessie
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. [electronic resource] - Cancer cell Dec 2010 - 683-95 p. digital
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
1878-3686
10.1016/j.ccr.2010.11.023 doi
Cell Line, Tumor
Drug Resistance, Neoplasm
Humans
MAP Kinase Signaling System
Melanoma--drug therapy
Mitogen-Activated Protein Kinase Kinases--antagonists & inhibitors
Phosphatidylinositol 3-Kinases--physiology
Phosphoinositide-3 Kinase Inhibitors
Phosphorylation
Proto-Oncogene Proteins B-raf--antagonists & inhibitors
Proto-Oncogene Proteins c-akt--metabolism
Receptor, IGF Type 1--antagonists & inhibitors
raf Kinases--physiology
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. [electronic resource] - Cancer cell Dec 2010 - 683-95 p. digital
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
1878-3686
10.1016/j.ccr.2010.11.023 doi
Cell Line, Tumor
Drug Resistance, Neoplasm
Humans
MAP Kinase Signaling System
Melanoma--drug therapy
Mitogen-Activated Protein Kinase Kinases--antagonists & inhibitors
Phosphatidylinositol 3-Kinases--physiology
Phosphoinositide-3 Kinase Inhibitors
Phosphorylation
Proto-Oncogene Proteins B-raf--antagonists & inhibitors
Proto-Oncogene Proteins c-akt--metabolism
Receptor, IGF Type 1--antagonists & inhibitors
raf Kinases--physiology